So far, the only fully human immunoglobulin G1 kappa anti-CD27 monoclonal antibody [123] is Varlilumab (CDX-1127), which interacts with the CD70-binding site and serves as an agonist of CD27.In phase I clinical trial exploring the safety and pharmacokinetics of CDX-1127 in patients suffering from selected refractory or relapsed hematologic malignancies or solid tumors (NCT01460134). This evidence concerns the gene CD27 and hematologic disorder.